Is Fulvestrant an endocrine drug?

Fulvestrant (Fulvestrant) is an endocrine therapy drug. It is an estrogen receptor antagonist and is used to treat breast cancer, especially those that are estrogen receptor positive.

Some tumor cells in breast cancer have estrogen receptors, which allow estrogen to stimulate their growth. Fulvestrant inhibits the activity of the estrogen receptor signaling pathway by competitively binding to the estrogen receptor, preventing estrogen from entering the receptor and activating it. This reduces the ability of tumor cells to proliferate, slowing or stopping tumor growth.

Because fulvestrant's effects are related to the estrogen signaling pathway in the body, it is classified as an endocrine therapy drug. This treatment method is different from traditional chemotherapy in that it does not directly kill tumor cells, but inhibits their proliferation by affecting the growth signals of tumor cells.

However, it is important to note that fulvestrant is commonly used in patients with breast cancer, especially if it is estrogen receptor positive. When using fulvestrant or any other treatment, patients should follow their doctor's recommendations and undergo regular monitoring to ensure the drug's efficacy and safety.

Fulvestrant injection has been launched in China and has been included in medical insurance. Patients can buy it domestically. The price of domestically imported original drugs is around 5,000 to 6,000 yuan, while domestic drugs are slightly cheaper. For specific prices, please consult the local hospital pharmacy or the medical insurance bureau. There is only Fulvestrant's original drug abroad. The cheaper original drugs are mainly the Turkish original drug and the Indian version of the original drug. The price is around 1,000~2,000 yuan, and the ingredients and efficacy of the original drugs at home and abroad are the same.